Valuation: Orthocell Limited

Market Cap 212M 152M 131M 123M 112M 211M 14.52B 1.45B 562M 7.32B 571M 559M 24.26B P/E 2026 *
-19.5x
P/E 2027 * -39x
Enterprise Value 170M 122M 104M 98.01M 89.52M 169M 11.6B 1.16B 450M 5.85B 457M 447M 19.39B EV / Sales 2026 *
14.8x
EV / Sales 2027 * 8.49x
Free-Float
83.71%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member 60 21/03/2006
Director/Board Member 60 08/03/2023
Chairman - 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 152M
+0.89%+3.29%+29.73%+17.01% 234B
-0.28%+1.83%+4.42%-15.72% 151B
-0.38%-6.86%-21.90%+24.49% 131B
-3.39%-7.38%-54.72%-5.10% 69.81B
-0.10%-1.63%+11.70%+19.18% 52.33B
-1.11%-1.80%-16.89%-13.58% 50.91B
+0.20%-0.21%+31.09%+29.58% 43.8B
-0.07%-0.40%+39.86%+51.51% 40.69B
-0.38%+2.19%-17.35%+46.41% 34B
Average -0.32%+0.04%+0.66%+17.09% 89.79B
Weighted average by Cap. -0.14%-0.04%+3.83%+12.05%

Financials

2026 *2027 *
Net sales 11.45M 8.21M 7.04M 6.61M 6.04M 11.4M 783M 78.23M 30.32M 395M 30.81M 30.14M 1.31B 21.55M 15.44M 13.26M 12.44M 11.36M 21.45M 1.47B 147M 57.06M 743M 57.99M 56.73M 2.46B
Net income -12.7M -9.1M -7.81M -7.33M -6.7M -12.64M -868M -86.78M -33.63M -438M -34.18M -33.43M -1.45B -8.55M -6.13M -5.26M -4.94M -4.51M -8.51M -584M -58.42M -22.64M -295M -23.01M -22.51M -977M
Net Debt -42.6M -30.53M -26.2M -24.6M -22.46M -42.4M -2.91B -291M -113M -1.47B -115M -112M -4.87B -29.5M -21.14M -18.15M -17.03M -15.56M -29.36M -2.02B -202M -78.11M -1.02B -79.38M -77.66M -3.37B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-